Transcript Diapositive 1 - The European Respiratory Society

Thank you for viewing this presentation.
We would like to remind you that this
material is the property of the author.
It is provided to you by the ERS for your
personal use only, as submitted by the
author.
 2012 by the author
17/07/2015
M/XDR-TB:
WHAT ARE THE UNRESOLVED PROBLEMS?
Jean-Pierre Zellweger, MD
Swiss Lung Association
Faculty disclosure
• I am a clinician caring for patients and fed up by errors and
mismanagement of TB and MDR-TB
• I have no interest in any organization or industry making profit from
MDR-TB (who will anyway?)
• Most of the data I will present are from WHO or ECDC reports. I
have no personal or secret data to present
M/XDR-TB UNRESOLVED PROBLEMS:
1. EPIDEMIOLOGY
• The number of M/XDR-TB cases is increasing
worldwide
• The increase concerns in particular Eastern
Europe and Central Asia
• In some countries, the proportion of MDR-TB
increases in spite of a decrease in the rate of TB
• The surveillance and the available data are far
from comprehensive.
TREND IN TOTAL TB, MDR-TB AND
PROPORTION OF MDR-TB IN NEW CASES
MDR-TB: GLOBAL BURDEN OF DISEASE
M/XDR-TB UNRESOLVED PROBLEMS:
2. DIAGNOSIS
• Insufficient diagnostic capacities in many
countries
• Insufficient use of cultures and DST
• Insufficient support of lab networks by local
authorities
M/XDR-TB UNRESOLVED PROBLEMS:
3. CHOICE OF TREATMENT
• Niveau 1
– Niveau 2
• Niveau 3
– Niveau 4
» Niveau 5
M/XDR-TB UNRESOLVED PROBLEMS:
3. CHOICE OF TREATMENT
• There are Guidelines but few recommendations
are based on a strong evidence
• The best Guidelines are useless if the drugs
are not available
• The best drugs are useless if the patients do
not tolerate them
• Sotgiu G et al, Eur Respir J 2012:40(2) 500
/ 400’000
M/XDR-TB UNRESOLVED PROBLEMS:
3. OUTCOME OF TREATMENT
• The outcome of treatment – if known – is still
below the expected standards
• Patients treated in a GLC-supported
programme have a better outcome (because the
best drugs are available)
TREATMENT OUTCOME BY WHO REGION,
2010 REPORTING YEAR
WHO European Region
Other WHO Regions
100%
7
90%
80%
6
1
6
1
5
2
4
3
10
5
1
3
3
1
1
2
4.3
6.1
7.3
6.7
11.3
14.1
8
11.3
1
5
9.0
13.0
70%
93
88
88
60%
80
9.3
76
68.7
11.3
50%
56.3
40%
AFR
AMR
Not evaluated
EMR
SEAR
Defaulted
New pulmonary
lab.confirmed
WPR
Failed
Died
Re-treated
lab confirmed
Successfully treated
MDR-TB cohort
M/XDR-TB UNRESOLVED PROBLEMS:
4. MANAGEMENT OF ADVERSE EVENTS
• Adverse events are frequent and may be severe
• Treatment of adverse events means – in the best
of cases – the use of further drugs (if available)
or interruption of treatment
ADVERSE EVENTS DURING TREATMENT OF
MDR-TB
• 1027 patients with MDR-TB treated in Latvia
– Adverse events in 79%
• Nausea (58%)
• Vomiting (39%)
• Abdominal pain (24%)
• Serious psychiatric episodes (13%)
• Hepatitis (9%)
• Real failure (4%)
– Change in drug dosage in 20%
– Discontinuation of one or more drug in 64%
Bloss E, IJTLD 2010;14(3):275
M/XDR-TB UNRESOLVED PROBLEMS:
5. CASE HOLDING
• Cas holding is – still –not a tradition in many
countries
• Even if needed, DOT is frequently not possible
because there are no outreach workers to do
the job and there are many administrative
obstacles
MANAGEMENT OF AN OUTBREAK OF MDR-TB:
IMPACT OF DOT ON DEATH RATE
• The Chuuk experience
Brostrom R, AJPH 2011;101(1):14-18
M/XDR-TB UNRESOLVED PROBLEMS:
6. COSTS OF TREATMENT
• The treatment of MDR-TB is 10-20 times more
expensive than the treatment of drug-sensitive
TB
• MDR-TB can ruin the budget of TB in countries
with weak economy
• In many developed countries, the treatment of
MDR-TB is more expensive than cardiac
transplantation
• Who can afford it?
M/XDR-TB UNRESOLVED PROBLEMS:
7. INFECTION CONTROL
• Hospitals are a perfect place for the
transmission of MDR-TB
• Implementing all infection control measures can
only prevent a part of all cases transmitted in
hospital settings
• How to prevent the transmission of MDR-TB to
other patients, HCW and visitors?
• How to manage contacts of MDR-TB cases who
have been infected?
OUTBREAK MANAGEMENT OF MDR-TB
• 2 independent but simultaneous outbreaks of MDR-TB
observed in July 2008 in the State of Micronesia
• 232 contacts identified, 139 examined:
– 15 MDR-TB
– 5 drug-sensitive TB
– 119 infected
• 105 offered preventive therapy with quinolone+E or
quinolone +ethio
• 93 completed the preventive treatment  0 TB
– 28 contacts without preventive treatment (2/14 refusal)
developed TB between 2008 and 2012
M/XDR-TB UNRESOLVED PROBLEMS:
8. PALLIATIVE CARE
• Back to sanatoria, fresh air, rich meals and
morphine (and large graveyards)?
M/XDR-TB UNRESOLVED PROBLEMS:
9. PREVENTION
• MDR-TB is a problem because errors have
been committed and are perpetuated
• As long as these errors will not be
acknowledged and corrected, there will be no
prospect for a decrease
M/XDR-TB UNRESOLVED PROBLEMS:
10. LEGAL ISSUES
• In many settings, legal issues (laws,
regulations and Guidelines) are an obstacle to
the adeqate management of TB and MDR-TB
• The committment of the governments should
start with the updating of the laws and
regulations
MDR-TB: TURN OFF THE TAP!
IF NOT…
TRENDS IN M/XDR-TB BY REGION (WHO
REPORT 2012)